Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS (2019) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in. Neuro Oncol 21(5):1–100

Article  Google Scholar 

Barr AR, Gergely F (2007) Aurora-A: the maker and breaker of spindle poles. J Cell Sci 120(Pt 17):2987–2996. https://doi.org/10.1242/jcs.013136

Article  CAS  Google Scholar 

Lehman NL, O’Donnell JP, Whiteley LJ, Stapp RT, Lehman TD, Roszka KM, Schultz LR, Williams CJ, Mikkelsen T, Brown SL, Ecsedy JA, Poisson LM (2012) Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. Cell Cycle 11(3):489–502. https://doi.org/10.4161/cc.11.3.18996

Article  CAS  Google Scholar 

Qiao W, Guo B, Zhou H, Xu W, Chen Y, Liang Y, Dong B (2017) miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA. Biochem Biophys Res Commun 486(1):43–48. https://doi.org/10.1016/j.bbrc.2017.02.120

Article  CAS  Google Scholar 

Asteriti IA, Giubettini M, Lavia P, Guarguaglini G (2011) Aurora-A inactivation causes mitotic spindle pole fragmentation by unbalancing microtubule-generated forces. Mol Cancer 10:131. https://doi.org/10.1186/1476-4598-10-131

Article  CAS  Google Scholar 

Zumbar CT, Usubalieva A, King PD, Li X, Mifsud CS, Dalton HM, Sak M, Urio S, Bryant WM, McElroy JP, Farmer G, Lehman NL (2018) The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells. J Neurooncol 137(3):481–492. https://doi.org/10.1007/s11060-018-2755-2

Article  CAS  Google Scholar 

Sak M, Zumbar CT, King PD, Li X, Mifsud CS, Usubalieva A, Anderson CD, Chesnick HM, McElroy JP, Chakravarti A, Burton EC, Lehman NL (2019) Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells. J Neurooncol. https://doi.org/10.1007/s11060-019-03164-5

Article  Google Scholar 

Van Brocklyn JR, Wojton J, Meisen WH, Kellough DA, Ecsedy JA, Kaur B, Lehman NL (2014) Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma. Cancer Res 74(19):5364–5370. https://doi.org/10.1158/0008-5472.CAN-14-0386

Article  CAS  Google Scholar 

Hong X, O’Donnell JP, Salazar CR, Van Brocklyn JR, Barnett KD, Pearl DK, deCarvalho AC, Ecsedy JA, Brown SL, Mikkelsen T, Lehman NL (2014) The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation. Cancer Chemother Pharmacol 73(5):983–990. https://doi.org/10.1007/s00280-014-2430-z

Article  CAS  Google Scholar 

Zou Z, Yuan Z, Zhang Q, Long Z, Chen J, Tang Z, Zhu Y, Chen S, Xu J, Yan M, Wang J, Liu Q (2012) Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy 8(12):1798–1810. https://doi.org/10.4161/auto.22110

Article  CAS  Google Scholar 

Heimans JJ, Vermorken JB, Wolbers JG, Eeltink CM, Meijer OW, Taphoorn MJ, Beijnen JH (1994) Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann Oncol 5(10):951–953. https://doi.org/10.1093/oxfordjournals.annonc.a058736

Article  CAS  Google Scholar 

Fitzgerald DP, Emerson DL, Qian Y, Anwar T, Liewehr DJ, Steinberg SM, Silberman S, Palmieri D, Steeg PS (2012) TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol Cancer Ther 11(9):1959–1967. https://doi.org/10.1158/1535-7163.MCT-12-0061

Article  CAS  Google Scholar 

Tsujimoto Y (1998) Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells 3(11):697–707. https://doi.org/10.1046/j.1365-2443.1998.00223.x

Article  CAS  Google Scholar 

Williams B, Zumbar C, Sak M, Lehman N (2020) EXTH-22 The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib improve survival in vivo. Neuro Oncol 22(2):91–91

Article  Google Scholar 

Chen J, Ananthanarayanan B, Springer KS, Wolf KJ, Sheyman SM, Tran VD, Kumar S (2020) Suppression of LIM kinase 1 and LIM kinase 2 limits glioblastoma invasion. Cancer Res 80(1):69–78. https://doi.org/10.1158/0008-5472.CAN-19-1237

Article  CAS  Google Scholar 

Vermeulen K, Berneman ZN, Van Bockstaele DR (2003) Cell cycle and apoptosis. Cell Prolif 36(3):165–175. https://doi.org/10.1046/j.1365-2184.2003.00267.x

Article  CAS  Google Scholar 

Lu Z, Miao Y, Muhammad I, Tian E, Hu W, Wang J, Wang B, Li R, Li J (2017) Colistin-induced autophagy and apoptosis involves the JNK-Bcl2-Bax signaling pathway and JNK-p53-ROS positive feedback loop in PC-12 cells. Chem Biol Interact 277:62–73. https://doi.org/10.1016/j.cbi.2017.08.011

Article  CAS  Google Scholar 

Kim H, Watanabe S, Kitamatsu M, Watanabe K, Ohtsuki T (2020) Cell cycle dependence of apoptosis photo-triggered using peptide-photosensitizer conjugate. Sci Rep 10(1):19087. https://doi.org/10.1038/s41598-020-76100-7

Article  CAS  Google Scholar 

Katayama H, Wang J, Treekitkarnmongkol W, Kawai H, Sasai K, Zhang H, Wang H, Adams HP, Jiang S, Chakraborty SN, Suzuki F, Arlinghaus RB, Liu J, Mobley JA, Grizzle WE, Wang H, Sen S (2012) Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell 21(2):196–211. https://doi.org/10.1016/j.ccr.2011.12.025

Article  CAS  Google Scholar 

Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN, Richmond A (2015) MDM2 and Aurora kinase A inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res 75(1):181–193. https://doi.org/10.1158/0008-5472.CAN-14-2405

Article  CAS  Google Scholar 

Hemann MT, Lowe SW (2006) The p53-Bcl-2 connection. Cell Death Differ 13(8):1256–1259. https://doi.org/10.1038/sj.cdd.4401962

Article  CAS  Google Scholar 

Sasai K, Treekitkarnmongkol W, Kai K, Katayama H, Sen S (2016) Functional significance of Aurora kinases-p53 protein family interactions in cancer. Front Oncol 6:247. https://doi.org/10.3389/fonc.2016.00247

Article  Google Scholar 

Huang XF, Luo SK, Xu J, Li J, Xu DR, Wang LH, Yan M, Wang XR, Wan XB, Zheng FM, Zeng YX, Liu Q (2008) Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 111(5):2854–2865. https://doi.org/10.1182/blood-2007-07-099325

Article  CAS  Google Scholar 

Hou D, Che Z, Chen P, Zhang W, Chu Y, Yang D, Liu J (2018) Suppression of AURKA alleviates p27 inhibition on Bax cleavage and induces more intensive apoptosis in gastric cancer. Cell Death Dis 9(8):781. https://doi.org/10.1038/s41419-018-0823-3

Article  CAS  Google Scholar 

Ciechomska IA, Gielniewski B, Wojtas B, Kaminska B, Mieczkowski J (2020) EGFR/FOXO3a/BIM signaling pathway determines chemosensitivity of BMP4-differentiated glioma stem cells to temozolomide. Exp Mol Med 52(8):1326–1340. https://doi.org/10.1038/s12276-020-0479-9

Article  CAS  Google Scholar 

Guan H, Song L, Cai J, Huang Y, Wu J, Yuan J, Li J, Li M (2011) Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells. PLoS ONE 6(5):19946

Article  Google Scholar 

Moustafa-Kamal M, Gamache I, Lu Y, Li S, Teodoro JG (2013) BimEL is phosphorylated at mitosis by Aurora A and targeted for degradation by betaTrCP1. Cell Death Differ 20(10):1393–1403. https://doi.org/10.1038/cdd.2013.93

Article  CAS  Google Scholar 

Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH, Coombes RC, Lam EW (2003) FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 278(50):49795–49805. https://doi.org/10.1074/jbc.M309523200

Article  CAS  Google Scholar 

Cartron PF, Loussouarn D, Campone M, Martin SA, Vallette FM (2012) Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme. Cell Death Dis 3:421

Article  Google Scholar 

Rieger L, Weller M, Bornemann A, Schabet M, Dichgans J, Meyermann R (1998) BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. J Neurol Sci 155(1):68–75. https://doi.org/10.1016/s0022-510x(97)00277-3

Article  CAS  Google Scholar 

Xia JL, Fan WJ, Zheng FM, Zhang WW, Xie JJ, Yang MY, Kamran M, Wang P, Teng HM, Wang CL, Liu Q (2017) Inhibition of AURKA kinase activity suppresses collective invasion in a microfluidic cell culture platform. Sci Rep 7(1):2973. https://doi.org/10.1038/s41598-017-02623-1

Article  CAS  Google Scholar 

Chen C, Song G, Xiang J, Zhang H, Zhao S, Zhan Y (2017) AURKA promotes cancer metastasis by regulating epithelial-mesenchymal transition and cancer stem cell properties in hepatocellular carcinoma. Biochem Biophys Res Commun 486(2):514–520. https://doi.org/10.1016/j.bbrc.2017.03.075

Article  CAS  Google Scholar 

Boiarska Z, Passarella D (2021) Microtubule-targeting agents and neurodegeneration. Drug Discov Today 26(2):604–615. https://doi.org/10.1016/j.drudis.2020.11.033

Article  CAS  Google Scholar 

Mitchell D, Bergendahl G, Ferguson W, Roberts W, Higgins T, Ashikaga T, DeSarno M, Kaplan J, Kraveka J, Eslin D, Werff AV, Hanna GK, Sholler GL (2016) A Phase 1 trial of TPI 287 as a single agent and in combination with temozolomide in patients with refractory or recurrent neuroblastoma or medulloblastoma. Pediatr Blood Cancer 63(1):39–46. https://doi.org/10.1002/pbc.25687

Article  CAS  Google Scholar 

Cortice Biosciences Final results from the dose-escalation stage of a phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma. http://meetinglibrary.asco.org/record/146708/abstract. ASCO Meeting Library. Accessed date 25 May 2017

MD Anderson Cancer Center (2018) Phase I/II bevacizumab versus bevacizumab plus TPI 287 for recurrent glioblastoma. https://clinicaltrials.gov/ct2/show/NCT01582152. Accessed 16 Feb 2022

Wetmore C, Boyett J, Li S, Lin T, Bendel A, Gajjar A, Orr BA (2015) Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. Neuro Oncol 17(6):882–888. https://doi.org/10.1093/neuonc/nov017

Article  CAS  Google Scholar 

Song A, Andrews DW, Werner-Wasik M, Kim L, Glass J, Bar-Ad V, Evans JJ, Farrell CJ, Judy KD, Daskalakis C, Zhan T, Shi W (2019) Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas. Radiother Oncol 132:135–141. https://doi.org/10.1016/j.radonc.2018.12.019

Article  CAS  Google Scholar 

Takeda (Millennium Pharmaceuticals Inc) (2019) A phase I clinical and pharmacodynamic study of MLN8237, a novel Aurora A kinase inhibitor, in participants with advanced malignancies. ClinicalTrials.gov Identifier: NCT00651664. https://clinicaltrials.gov/ct2/show/NCT00651664. Accessed 16 Feb 2022

Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ (2019) Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer: A randomized clinical trial. JAMA Oncol 5(1):183773

Article